RGNX Fair Value Estimate
$8.2343.9% undervalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Regenxbio Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
Current Price
$5.72
-8.41%GoodMoat Value
$8.23
43.9% undervaluedProfile
Valuation (TTM)
Market Cap$295.23M
P/E-1.02
EV—
P/B2.87
Shares Out51.61M
P/Sales3.36
Revenue$87.82M
EV/EBITDA—
Regenxbio Inc (RGNX) Valuation
RGNX Valuation Metrics
FCF$-126.38M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →RGNX Valuation & Fair Value Analysis
Regenxbio Inc (RGNX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Regenxbio Inc is $8.23. The current stock price is $5.72, suggesting the stock is 43.9% undervalued.
The price-to-earnings (P/E) ratio is -1.02. Price-to-book ratio is 2.87. Price-to-sales ratio is 3.36. PEG ratio is 0.00.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Regenxbio Inc's intrinsic value.